Clinical Trial

Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients

Name: Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients — clinical trial record (NCT07181239)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The purpose of this study is to compare the efficacy between CM336 and investigator's choice Standard of Care in relapsed or refractory multiple myeloma (RRMM) patients.

Trial Details

NCT Number	NCT07181239
Lead Sponsor	Keymed Biosciences Co.Ltd
Conditions	Multiple Myeloma (MM)
Enrollment	280 participants
Start Date	2025-09
Primary Completion	2027-09 (estimated)
Study Completion	2030-04 (estimated)
Updated on ClinicalTrials.gov	2025-09-18